New In-Home UVB Phototherapy Device Receives FDA 510 (k) Clearance for Psoriasis

Lerner Medical Devices, Inc., recently announced that Levia, a novel, in-home, ultraviolet B (UVB) phototherapy device, has received 510 (k) clearance from the FDA for treatment of psoriasis and certain other skin conditions such as vitiligo. Under the direction of a physician, Levia allows patients to treat their chronic scalp and small area psoriasis privately with a safe and effective non-drug option: Personal Targeted Phototherapy, according to Lerner Medical Devices. Patients can manage the delivery of their physician-prescribed treatment regimens using Levia's proprietary touch-screen user interface in the privacy of their own homes. Levia's proprietary beam delivery attachments, Lite-Brush and Lite-Spot, direct UVB light to the affected areas of scalp and skin, according to company materials, which claims this precise targeting minimizes exposure of uninvolved areas and ensures controlled and rapid treatment. John R. Lyon, CEO of Lerner Medical, said in a press release,"UVB phototherapy is a proven, non-systemic treatment for psoriasis, which is under-utilized, because, as a cumulative therapy, it requires multiple office visits, with attendant multiple co-pays. Levia and Personal Targeted Phototherapy now offer psoriasis patients and their physicians the ability to utilize the non-drug option of UVB light in a private home environment, with a highly efficient treatment regimen and built-in safeguards. We believe that Personal Targeted Phototherapy with Levia represents a new standard of therapeutic effectiveness, convenience and control in the treatment of psoriasis. We expect Levia to be available to patients in the first quarter of 2010." For more information about Levia, please visit www.mylevia.com.